- 70% reach target blood pressure reduction for 24 hours

- Excellent effect of 21.4mmHg in systolic pressure

- Particularly effective for morning hypertension patients



Sevika, an antihypertensive agent (Olmesartan+Amlodipine Besylate) co-promoted by Korea Daiichisankyo (President Kim Dae Jung) and Daewoong Pharmaceutical Co., Ltd (President Lee Jong Wook), was confirmed to have a 24-hour BP reduction effect. This was published in AZTEC study (AZOR Trial Evaluating Blood Pressure Reductions and Control) and in the online version of Therapeutic Advances in Cardiovascular Disease, a UK publication. 

This research was performed for 16 weeks on 185 hypertension patients over 18 years of age. The blood pressure was measured by administering 5mg/day of amlopidine for 3 weeks. If target BP of 120/80mmHg was not reached, amlopidine/olmesartan complex was administered at 5/20mg, 5/40mg and 10/40mg.

As a result, it was found that Sevikar reached target BP for 24 hours (70.9%), and had an excellent BP reduction in systolic pressure compared with placebo at 21.4mmHg. In particular, the target pressure was examined at 130/80mmHg, 125/75mmHg and 120/80 mmHg respectively, and each showed an excellent BP reaching rate. Thus, Sevikar is proven as a 24-hours effective antihypertensive agent. 

For BP patients, 24 hours BP control is of great importance because there is a sudden increase in BP in the morning. As ‘morning hypertension’ is more risky for a stroke or myocardial infarction, specialists emphasize the need for24 hours continual BP control and prevention of any complications.

Jeong Jae Woong, Daewoong Sevicar PM, remarked "it is inevitably necessary for hypertension patients to maintain 24 hours HP reduction. This research proved Sevikar is particularly effective and safe for patients with morning hypertension."